---
title: "STTK: Lead DR3 antibody SL-325 shows promise for IBD with strong safety and low immunogenicity"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292627952.md"
description: "Pioneering DR3-targeted antibodies, the pipeline aims to address unmet needs in IBD and other immune diseases. Lead candidate SL-325 showed strong safety, durable efficacy, and low immunogenicity in Phase 1, with a Phase 2b Crohn's trial set for Q3 2026. Cash reserves support operations into 2029.Original document: Shattuck Labs, Inc. [STTK] Slides Release — Jul. 14 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-14T12:45:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292627952.md)
  - [en](https://longbridge.com/en/news/292627952.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292627952.md)
generator: "portal-rs"
---

# STTK: Lead DR3 antibody SL-325 shows promise for IBD with strong safety and low immunogenicity

Pioneering DR3-targeted antibodies, the pipeline aims to address unmet needs in IBD and other immune diseases. Lead candidate SL-325 showed strong safety, durable efficacy, and low immunogenicity in Phase 1, with a Phase 2b Crohn's trial set for Q3 2026. Cash reserves support operations into 2029.

Original document: Shattuck Labs, Inc. \[STTK\] Slides Release — Jul. 14 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [STTK.US](https://longbridge.com/en/quote/STTK.US.md)

## Related News & Research

- [Connor Clark & Lunn Investment Management Ltd. Invests $1.99 Million in Shattuck Labs, Inc. $STTK](https://longbridge.com/en/news/297417449.md)
- [Shattuck Labs posts investor deck spotlighting DR3-blocking antibody SL-325 for inflammatory diseases](https://longbridge.com/en/news/295529846.md)
- [Nvidia Expands AI Partnership With Amazon Web Services](https://longbridge.com/en/news/297671725.md)
- [DWTX: Halneuron shows promise as a scalable, effective CINP therapy with strong Phase 2 results](https://longbridge.com/en/news/297686345.md)
- [Zenas Biopharma outlines autoimmune disease pipeline in corporate presentation](https://longbridge.com/en/news/297813603.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**